Anatara Lifesciences’ Gastrointestinal ReProgramming (GaRP) dietary supplement was recently included in Biospace’s latest Inflammatory Bowel Disease Insight Report as a preclinical candidate in the IBD drug pipeline.
Anatara Lifesciences’ lead human health product is referred to as GaRP (Gastrointestinal ReProgramming). The GaRP product is a microbiome-targeted multi-component dietary supplement that has been designed to address the primary underlying factors associated with IBD and IBS. It is being positioned as an adjunct to existing therapies and not to replace existing prescription medications. Antara has completed the preclinical program, which provided strong scientific evidence that GaRP can combat the underlying causes of chronic bowel conditions, including inflammation and dysbiosis of the microbiome.
Click the following link for access to the full article: